Novo Nordisk's Wegovy wins FDA approval for cutting heart disease risks, in move that could expand insurance coverage
That decision could widen insurance coverage for the drug and similar treatments for obesity, which has been a major barrier to access for patients.
That decision could widen insurance coverage for the drug and similar treatments for obesity, which has been a major barrier to access for patients.
